|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Oncomed Pharmaceuticals Inc
| | | Phone: | (650) 995-8200 | Fax: | (650) 298-8600 | Year Established: | 2004 | Employees: | 64 | Ticker: | OMED | Exchange: | NASDAQ | Main Contact: | Sunil Patel, Senior VP, Corporate Development & Finance, & CFO | | Other Contacts: | Rainer K. Brachmann, M.D., VP, Clinical Development Ann Kapoun, Ph.D., VP, Translational Medicine Jill Henrich, VP, Regulatory Affairs Robert Stagg, Pharm.D., VP, Clinical Research Alicia J. Hager, J.D., Ph.D., VP, General Counsel Tim Hoey, Ph.D., Senior VP, Cancer Biology John Lewicki, Ph.D., Executive VP & CSO Austin Gurney, Ph.D., Senior VP, Molecular and Cellular Biology
| | Company Description | OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), anti-Notch 2/3 (OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-Fzd7, OMP-18R5), and Fzd8-Fc (OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, anti-DLL4/anti-VEGF bispecific (OMP-305B83) and anti-RSPO3, with Investigational New Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). | |
|
|
|
|
|